IINN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Inspira Technologies Oxy BHN Ltd (IINN) is not a strong buy for a beginner, long-term investor at this time. The technical indicators are bearish, there is no significant trading sentiment from hedge funds or insiders, and the company's financials show no growth trends. While the recent news regarding the ART100 platform approval is positive, it does not outweigh the overall weak technical and financial outlook. A hold strategy is recommended for now.
The MACD is negative and expanding (-0.00964), indicating bearish momentum. The RSI is neutral at 22.513, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 0.583 and S2 at 0.525, suggesting further downside risk.
The ART100 platform received approval from Clalit Health Services, marking its commercial availability and enhancing the company's competitiveness in the medical device market.
Technical indicators are bearish, and there is no significant trading activity or sentiment from hedge funds or insiders. Additionally, the company's financial performance shows no growth, with negative net income and EPS.
In Q4 2023, the company reported no revenue growth (0% YoY), a net income of -$3,008,000, and an EPS of -0.24. Gross margin increased to 0.69 but remains insufficient to indicate strong financial health.
No recent analyst ratings or price target changes are available for IINN.
